Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells

References

• Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, et al. Medullary carcinoma. J Natl Compr Canc Netw 2010; 8:512-30; PMID:20495082; https://doi.org/10.6004/jnccn.2010.0040
   PubMed Web of Science ®Google Scholar
• Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004; 204:197-211; PMID:15013219; https://doi.org/10.1016/S0304-3835(03)00456-7
   PubMed Web of Science ®Google Scholar
• Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013; 98:E364-9; PMID:23264394; https://doi.org/10.1210/jc.2012-2703
   PubMed Web of Science ®Google Scholar
• Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013; 23:50-7; PMID:23240926; https://doi.org/10.1089/thy.2012.0207
   PubMed Web of Science ®Google Scholar
• Degrauwe N, Sosa JA, Roman S, Deshpande HA. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol 2012; 6:243-52. PMID:22723734; https://doi.org/10.4137/CMO.S7999
   PubMedGoogle Scholar
• Nagilla M, Brown RL, Cohen EE. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther 2012; 29:925-34; PMID:23104465; https://doi.org/10.1007/s12325-012-0060-6
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134-41; PMID:22025146; https://doi.org/10.1200/JCO.2011.35.5040
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31:3639-46; PMID:24002501; https://doi.org/10.1200/JCO.2012.48.4659
   PubMed Web of Science ®Google Scholar
• Dadu R, Hu MN, Grubbs EG, Gagel RF. Use of tyrosine kinase inhibitors for treatment of medullary thyroid carcinoma. Recent Results Cancer Res 2015; 204:227-49; PMID:26494392; https://doi.org/10.1007/978-3-319-22542-5_11
   PubMedGoogle Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297-308; PMID:22439925; https://doi.org/10.1016/j.ccr.2012.02.014
   PubMed Web of Science ®Google Scholar
• Haq R, Fisher DE, Widlund HR. Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res 2014; 20:2257-63; PMID:24610826; https://doi.org/10.1158/1078-0432.CCR-13-0898
   PubMed Web of Science ®Google Scholar
• Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol 2013; 23:612-9; PMID:24060597; https://doi.org/10.1016/j.tcb.2013.08.003
   PubMed Web of Science ®Google Scholar
• Don AS, Hogg PJ. Mitochondria as cancer drug targets. Trends Mol Med 2004; 10:372-8; PMID:15310457; https://doi.org/10.1016/j.molmed.2004.06.005
   PubMed Web of Science ®Google Scholar
• Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat Rev Cancer 2014; 14:709-21; PMID:25342630; https://doi.org/10.1038/nrc3803
   PubMed Web of Science ®Google Scholar
• Starenki D, Park JI. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. J Clin Endocrinol Metab 2013; 98:1529-40; PMID:23509102; https://doi.org/10.1210/jc.2012-3671
   PubMed Web of Science ®Google Scholar
• Starenki D, Hong SK, Lloyd RV, Park JI. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells. Oncogene 2015; 34:4624-34; PMID:25435367; https://doi.org/10.1038/onc.2014.392
   PubMed Web of Science ®Google Scholar
• Starenki D, Park JI. Selective mitochondrial uptake of MKT-077 can suppress medullary thyroid carcinoma cell survival in vitro and in vivo. Endocrinol Metab (Seoul) 2015; 30(4):593-603; PMID:26485469; https://doi.org/10.3803/EnM.2015.30.4.593
   PubMedGoogle Scholar
• Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007; 47:629-56; PMID:17014364; https://doi.org/10.1146/annurev.pharmtox.47.120505.105110
   PubMed Web of Science ®Google Scholar
• Arthan D, Hong SK, Park JI. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett 2010; 297:31-41; PMID:20570039; https://doi.org/10.1016/j.canlet.2010.04.021
   PubMed Web of Science ®Google Scholar
• Park JI, Strock CJ, Ball DW, Nelkin BD. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 2003; 23:543-54; PMID:12509453; https://doi.org/10.1128/MCB.23.2.543-554.2003
   PubMed Web of Science ®Google Scholar
• Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine 2005; 29:125-34; PMID:15613280; https://doi.org/10.1016/j.cyto.2004.10.005
   PubMed Web of Science ®Google Scholar
• Dhanasekaran A, Kotamraju S, Karunakaran C, Kalivendi SV, Thomas S, Joseph J, Kalyanaraman B. Mitochondria superoxide dismutase mimetic inhibits peroxide-induced oxidative damage and apoptosis: role of mitochondrial superoxide. Free Radic Biol Med 2005; 39:567-83; PMID:16085176; https://doi.org/10.1016/j.freeradbiomed.2005.04.016
   PubMed Web of Science ®Google Scholar
• Hong SK, Yoon S, Moelling C, Arthan D, Park JI. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. J Biol Chem 2009; 284:33006-18; PMID:19805545; https://doi.org/10.1074/jbc.M109.012591
   PubMed Web of Science ®Google Scholar
• Cheng G, Zielonka J, Dranka BP, McAllister D, Mackinnon AC Jr, Joseph J, Kalyanaraman B. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res 2012; 72:2634-44; PMID:22431711; https://doi.org/10.1158/0008-5472.CAN-11-3928
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55; PMID:6382953; https://doi.org/10.1016/0065-2571(84)90007-4
   PubMedGoogle Scholar
• de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ, Hofstra RM. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006; 139:806-14; PMID:16782438; https://doi.org/10.1016/j.surg.2005.10.019
   PubMed Web of Science ®Google Scholar
• Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, et al. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J Endocrinol Invest 2007; 30:RC31-4; PMID:18075281; https://doi.org/10.1007/BF03349220
   PubMed Web of Science ®Google Scholar
• Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007; 282:29230-40; PMID:17664273; https://doi.org/10.1074/jbc.M703461200
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773:1263-84; PMID:17126425; https://doi.org/10.1016/j.bbamcr.2006.10.001
   PubMed Web of Science ®Google Scholar
• Salvi M. Receptor tyrosine kinases take a direct route to mitochondria: an overview. Curr Protein Pept Sci 2013; 14:635-40; PMID:24106960; https://doi.org/10.2174/13892037113146660087
   PubMed Web of Science ®Google Scholar
• Modica-Napolitano JS, Aprille JR. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 2001; 49:63-70; PMID:11377803; https://doi.org/10.1016/S0169-409X(01)00125-9
   PubMed Web of Science ®Google Scholar
• Lin TK, Hughes G, Muratovska A, Blaikie FH, Brookes PS, Darley-Usmar V, Smith RA, Murphy MP. Specific modification of mitochondrial protein thiols in response to oxidative stress: a proteomics approach. J Biol Chem 2002; 277:17048-56; PMID:11861642; https://doi.org/10.1074/jbc.M110797200
   PubMed Web of Science ®Google Scholar
• Smith RA, Adlam VJ, Blaikie FH, Manas AR, Porteous CM, James AM, Ross MF, Logan A, Cochemé HM, Trnka J, et al. Mitochondria-targeted antioxidants in the treatment of disease. Ann N Y Acad Sci 2008; 1147:105-11; PMID:19076435; https://doi.org/10.1196/annals.1427.003
   PubMed Web of Science ®Google Scholar
• Klein P, Muller-Rischart AK, Motori E, Schonbauer C, Schnorrer F, Winklhofer KF, Klein R. Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants. EMBO J 2014; 33:341-55; PMID:24473149; https://doi.org/10.1002/embj.201284290
   PubMed Web of Science ®Google Scholar
• Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph J, Kalyanaraman B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 2004; 279:37575-87; PMID:15220329; https://doi.org/10.1074/jbc.M404003200
   PubMed Web of Science ®Google Scholar
• Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, et al. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J 2009; 96:1388-98; PMID:19217856; https://doi.org/10.1016/j.bpj.2008.10.042
   PubMed Web of Science ®Google Scholar